Sangamo Therapeutics, Inc.’s Gross Margin at a glance
Sangamo Therapeutics, Inc. reports gross margin of 100% for Dec 2024. The prior period recorded 87.4% (Dec 2023). Year over year the metric moved +12.6 pts (+14.4%). The rolling three-period average stands at 92.2%. Data last refreshed Dec 7, 2025, 2:51 AM.
Latest reading
100% · Dec 2024
YoY movement
+12.6 pts (+14.4%)
Rolling average
92.2%
Current Gross Margin
100%
+12.6 pts
+14.4%
Rolling average
92.2%
Latest Value
100%
Dec 2024
YoY Change
+12.6 pts
Absolute
YoY Change %
+14.4%
Rate of change
3-Period Avg
92.2%
Smoothed
Narrative signal
Sangamo Therapeutics, Inc.’s gross margin stands at 100% for Dec 2024. Year-over-year, the metric shifted by +12.6 pts, translating into a +14.4% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How gross margin shapes Sangamo Therapeutics, Inc.'s story
As of Dec 2024, Sangamo Therapeutics, Inc. reports gross margin of 100%. Measure pricing power and cost of goods efficiency by reviewing historical gross margins.
Pricing versus input costs
Gross margin expands when pricing power or mix more than offset raw material and labor inflation.
Benchmark to peers
Compare margins within a sector to spot operational advantages or signs of discounting.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Sangamo Therapeutics, Inc. (SGMO) FAQs
Answers tailored to Sangamo Therapeutics, Inc.’s gross margin profile using the latest Financial Modeling Prep data.
What is Sangamo Therapeutics, Inc.'s current gross margin?
As of Dec 2024, Sangamo Therapeutics, Inc. reports gross margin of 100%. This reading reflects the latest filings and price data for SGMO.
How is Sangamo Therapeutics, Inc.'s gross margin trending year over year?
Year-over-year, the figure shifts by +12.6 pts (+14.4%). Pair this context with revenue growth and free cash flow signals to gauge momentum for SGMO.
Why does gross margin matter for Sangamo Therapeutics, Inc.?
Gross margin tracks the percentage of revenue remaining after direct production and service delivery costs. For Sangamo Therapeutics, Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Sangamo Therapeutics, Inc.'s gross margin above its recent average?
Sangamo Therapeutics, Inc.'s rolling three-period average sits at 92.2%. Comparing the latest reading of 100% to that baseline highlights whether momentum is building or fading for SGMO.
How frequently is Sangamo Therapeutics, Inc.'s gross margin refreshed?
Data for SGMO was last refreshed on Dec 7, 2025, 2:51 AM and updates automatically every 24 hours, keeping your valuation inputs current.